European Primary Care Cardiovascular Society

Lipids

Lecture (panel discussion) 3 out of 3

What are the implications for practice? - A discussion on COVID-19, ACE2 and RAASi

10' education - May 14, 2020 - Profs. John Deanfield, Jan Danser and Murray Epstein

A little closer to controlling LDL-c levels in HoFH with PCSK9i

3' education - Apr. 11, 2020 - Dirk Blom, PhD

Reduced CV risk with an intervention targeting identified barriers to care

3' education - Sep. 16, 2019 - Paris, France - Prof. J-D Schwalm

Lower LDL-c targets in the 2019 ESC/EAS Dyslipidaemia Guidelines: this is why

5' education - Sep. 9, 2019 - Prof. François Mach

The cardiovascular challenge for primary care in diabetes

10' education - Apr. 11, 2019 - EuroPrevent 2019 - Prof. Richard Hobbs, MD

Lowering remnants becomes more important, also in light of the obesity epidemic

3' education - June 19, 2019 - EAS 2019 - Prof. Børge Nordestgaard

EPCCS

3' education - Feb. 8, 2019

The cardiovascular challenge for primary care in diabetes

10' education - July 10, 2018 - Prof. Richard Hobbs - Oxford, UK

New cholesterol guidelines: aim therapy at patients at highest risk who will benefit most

3' education - Nov. 22, 2018 - Neil Stone, MD - Evanston and Chicago, IL, USA

Lipids and food

10' education - July 11, 2018 - Prof. David Marais - Cape Town, South Africa

Treatment of high-risk ACS patients may change based on ODYSSEY OUTCOMES study results

3' education - Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Dr. Valentin Fuster, New York, NY, USA

PCSK9 inhibitor has very good benefit-to-risk profile in high risk ACS patients in ODYSSEY OUTCOMES trial

3' education - Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Prof. Gabriel Steg - Paris, France

How do the latest guideline changes affect management of dyslipidaemia in primary care?

10' education - May 26, 2017

What is the evidence base for lipid modification in the guidelines updates?

10' education - Feb. 24, 2016 - Prague - EPCCS 2015

What's the evidence for BP and lipid targets in diabetes?

3' education - Nov. 25, 2014 - EPCCS 2014, Brussels
##SCROLLER_ITEMS_FULL_TITLE##

Cholesterol guideline breaking news in USA

3' education - Dec. 16, 2013 - AHA 2013 - Clyde Yancy

There is a gap between guidelines and clinical practice for lipid management

Literature - Sep. 30, 2020 - Ray KK, et al. - Eur J Prev Cardiol 2020

Attainment of 2016 guideline-recommended risk-based LDL-c goal was 54% and for 2019 risk-based LDL-c goal this was 33% in patients on lipid-lowering therapy in primary and secondary settings.

LDL-c reduction with PCSK9 inhibitor in pediatric HeFH patients

News - Sep. 9, 2020

ESC 2020 Evolocumab, in addition to standard lipid-lowering therapies, resulted in a placebo-corrected difference of 38.3% for LDL-c after 24 weeks in pediatric HeFH patients.

In patients with metabolic syndrome PCSK9 inhibitor is effective and safe

Literature - Aug. 19, 2020 - Deedwania P, et al. - JAMA Cardiol. 2020

Treatment with the PCSK9 inhibitor evolocumab reduced a composite of CV events compared to placebo in ASCVD patients with and without metabolic syndrome in a similar degree.

Differences between men and women in CV medication prescription prevalence in primary care

Literature - June 2, 2020 - Zhao M et al., - J Am Heart Assoc. 2020.

This systematic review and meta-analysis of 43 studies showed that the prescription prevalence in women was lower for aspirin, statins, and ACE inhibitors, but higher for diuretics, compared to men.

What are the implications for practice? - A discussion on COVID-19, ACE2 and RAASi

10' education - May 14, 2020 - Profs. John Deanfield, Jan Danser and Murray Epstein
As many questions arise on COVID-19, ACE2 and RAAS inhibition, 3 experts discuss some of the issues on this topic as part of a webinar.

As many questions arise on COVID-19, ACE2 and RAAS inhibition, 3 experts discuss some of the issues on this topic as part of a webinar.

Total vascular events reduced by statin treatment after stroke or TIA

Literature - May 7, 2020 - Szarek M, et al. - J Am Coll Cardiol. 2020

Total (first and subsequent) vascular events among patients with recent stroke or transient ischemic attack were reduced, as shown in a post-hoc analysis of the SPARCL trial.

A little closer to controlling LDL-c levels in HoFH with PCSK9i

3' education - Apr. 11, 2020 - Dirk Blom, PhD
Dirk Blom discusses the design and outcomes in the ODYSSEY HoFH trial, evaluating LDL-c lowering and safety of alirocumab in HoFH patients.

ACC 2020 Dirk Blom discusses the design and outcomes of the ODYSSEY HoFH trial, evaluating LDL-c lowering and safety of alirocumab in HoFH patients.

LDL-c reduced with PCSK9 inhibitor in patients with HoFH

News - Apr. 11, 2020

ACC 2020 The ODYSSEY HoFH trial demonstrated that treatment with alirocumab reduced LDL-c in HoFH patients compared to placebo, and alirocumab was found to be well tolerated and safe.

Sugar-sweetened beverage intake associated with adverse changes in HDL-c and triglycerides

Literature - Mar. 5, 2020 - Haslam DE et al., - J Am Heart Assoc. 2020.

High intake of sugar-sweetened beverages was associated with adverse changes in HDL-c and triglyceride, along with higher incidence of dyslipidemias related to low HDL-c and high triglyceride.

Initiating CV preventive medication can have both positive and negative effects on lifestyle

Literature - Feb. 10, 2020 - Korhonen MJ et al., - J Am Heart Assoc. 2020

Adults who started primary CV preventive pharmacotherapy showed higher BMI and more inactivity, but reduced smoking and alcohol consumption after about 4 years than those not taking drugs.

In normal BMI post-menopausal women, trunk fat was associated with higher and leg fat with lower CVD risk

Literature - Sep. 16, 2019 - Chen G-C et al., - Eur Heart J. 2019

Data of US postmenopausal women with normal BMI show that trunk fat and higher leg fat have opposing associations with CVD risk, while total body fat was not significantly related to CVD risk.

Reduced CV risk with an intervention targeting identified barriers to care

3' education - Sep. 16, 2019 - Paris, France - Prof. J-D Schwalm
In community-based studies in Colombia and Malaysia, HOPE-4 achieved reduced CV risk, better treatment adherence and healthier behavior with an intervention that targeted previously identified barriers to care.

ESC 2019 In community-based studies in Colombia and Malaysia, HOPE-4 achieved reduced CV risk, better treatment adherence and healthier behavior with an intervention that targeted previously identified barriers to care.